actrevo

actrevo GmbH is a Hamburg-based pharmaceutical company and full-service provider specializing in drug development, regulatory affairs, and market entry for the European Union. Founded in 2015, the company operates as a family-owned business, offering a range of services including EU-GMP compliance consulting, dossier preparation, and QP release. actrevo also markets its own portfolio of products, including Alltrevo (olopatadine) for allergic conjunctivitis, the Hialurom line of hyaluronic acid injections for osteoarthritis and tendon pain, and Rafaject, an atropine auto-injector for organophosphate poisoning. The company serves as a strategic partner for international manufacturers looking to establish their products in the EU healthcare market. With its own laboratory and Qualified Person (QP) services, actrevo manages the entire supply chain from import to analytical release.